

Sensorion Announces Its Participation in Several Investor Conferences to be Held in March

Montpellier, February 20, 2025, 7.30 am CET – Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces its participation in upcoming investor conferences taking place throughout March.

- Nawal Ouzren, Chief Executive Officer, and Laurene Danon, Chief Financial Officer, will participate in **Cowen's 45th Annual Health Care Conference**, which will be held in Boston, USA, on March 3-5, 2025. Sensorion's management team will be available for one-to-one meetings.
Nawal Ouzren will also make a Company presentation on March 3, 2025, at 3:10pm ET.
- Sensorion will participate in **Leerink's Partners Global Healthcare Conference**, in Miami, USA, taking place on March 10-12, 2025. Nawal Ouzren, Chief Executive Officer, will take part in a *fireside chat* with research analyst Lili Nsongo on March 10 at 2:20pm ET. Sensorion's management team will also be available for one-to-one meetings.

If you would like to meet Sensorion's management team, please contact us by email: ir.contact@sensorion-pharma.com.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion's portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders. Sensorion's clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, has completed in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

www.sensorion.com

Contacts

Investor Relations

Noémie Djokovic, Investor Relations and
Communication Associate
ir.contact@sensorion-pharma.com

Press Relations

Ulysse Communication
Bruno Arabian / 00 33(0)6 87 88 47 26
barabian@ulyse-communication.com
Nicolas Entz / 00 33 (0)6 33 67 31 54
nentz@ulyse-communication.com

Label: **SENSORION**
ISIN: **FR0012596468**
Mnemonic: **ALSEN**





Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.